期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用阿托伐他汀治疗原发性肾病综合征高脂血症的疗效观察 被引量：4

下载PDF
导出
摘要 目的探讨阿托伐他汀治疗原发性肾病综合征高脂血症的临床疗效。方法回顾分析120例患者的临床资料。结果治疗前后血脂改变同组内比较:经6～8周治疗后两组血清TC、TG、LDL-C较治疗前均明显下降(P<0.05),HDL-C轻度升高(P<0.05)。治疗组较对照组TC、TG、LDL-C下降明显(P<0.05)。结论口服阿托伐他汀吸收后不需要在体内激活即有生物活性,较其他他汀类药物起效更快,其蛋白结合率高,对HMG-CoA还原酶的抑制作用较同类药物强。本组无明显副反应出现,表明阿托伐他汀早期治疗肾病综合征高脂血症疗效满意,值得临床应用。
作者 李海云
机构地区 山西省文水县人民医院
出处 《中国实用医药》 2011年第3期164-165,共2页 China Practical Medicine
关键词 阿托伐他汀 原发性肾病综合征 高脂血症
分类号 R692.3 [医药卫生—泌尿科学]
  • 相关文献

参考文献8

二级参考文献19

  • 1[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 2[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 3[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 4[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 5[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 6[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 7[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.
  • 8[8]Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study[J]. Clin Ther 1996; 18: 853-63.
  • 9[9]Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants[J]. Circulation 1996; 94(8 Suppl): 583.
  • 10[10]Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia[J]. Atherosclerosis 1995; 115 Suppl: S20.

共引文献146

同被引文献30

  • 1方艺,丁小强,陈利明,滕杰,钟一红,傅辰生,邹建洲.二重滤过血浆置换治疗难治性高脂血症的近期和远期疗效[J].中国临床医学,2004,11(6):1061-1063. 被引量：3
  • 2吴苏舒,刘玉明,陈静.他汀类药物调脂外临床应用概况[J].药学实践杂志,2007,25(1):4-6. 被引量：8
  • 3王慧婷,史凯蕾,朱毅,石文蕾.颈动脉粥样硬化与冠心病的关系[J].国际心血管病杂志,2007,34(2):141-143. 被引量：9
  • 4Ringleb PA. Thrombolytics,anticoagulants,and antiplatelet agents[J].Stroke,2009,(02):312-313.
  • 5Tedgui A,Mlalat Z. Cytokines in atherosclerosis:pathogenic and regulatory pathways[J].Physiological Reviews,2008,(02):515-581.
  • 6龚德华,季大玺,朱冬冬,等.双重血浆置换联合他汀类降脂药对顽固性肾病综合征高胆固醇血症的治疗作用[c].北京:中华医学会肾脏病学会分会2011学术年会论文集,2011:178-179.
  • 7Lan J,Dong F,Yan Z,et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension[J]. J Ethnopharmacol,2014,10 (28) : 159-165.
  • 8Aguilar-Salinas CA,Barrett PH,Kelber J,et al. Physiologic me- chanisms of action of |ovastatin in nephrotic syndrome[J]. J Lipid Res, 1995,36(1 ) : 188-199.
  • 9Matzkies FK,Bahner U,Teschner M,et al.Efficiency of l-year treatment with fluvastatin in hyperlipidemic patients with ne- phritic syndrome[J]. Am J Nephrol, 1999,19(4) :492-494.
  • 10Olbtieht CJ,Wanner C,Thiery J,et al. Simvastatin in nephritic syndrome.Simvastatin in nephrotic syndrome study group[J]. Kidney Int Suppl, 1999,20(71 ) :$113-116.

二级引证文献10

中国实用医药
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部